Timothy Flanigan, MD
Infectious Disease · Providence, RINPI 1679512354
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,800 of the $2,029 with a category attached, or 88.7%. Valneva Austria GmbH accounts for 88.7% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $1,800 and has fallen 98.4% since, to $30 in 2023.
Across 4 payments — averaging $507.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valneva Austria GmbH$2K
- Abbott$229
Across 10 payments — averaging $20,142 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Valneva Austria GmbH$201K
What the payments were for
- Consulting fees$1,80089%
- Food & beverage$22911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valneva Austria GmbH | 1 | $1,800 |
| Abbott | 3 | $229 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$174
How this compares
$2,029 in reported general payments places this provider in the 80th percentile of 52 infectious disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 92 | $394,687 |
| DovatoDolutegravir Sodium/Lamivudine | 123 | $387,406 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 64 | $254,057 |
| TivicayDolutegravir Sodium | 51 | $123,121 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 32 | $116,401 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 22 | $80,829 |
| DescovyEmtricitabine/Tenofov Alafenam | 36 | $80,645 |
| JulucaDolutegravir/Rilpivirine | 19 | $66,473 |
| EliquisApixaban | 21 | $11,941 |
| Cephalexin | 19 | $6,691 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 30 | $5,580 |
| Darunavir | 11 | $5,207 |
| Nevirapine ErNevirapine | 12 | $2,125 |
| ValacyclovirValacyclovir Hcl | 43 | $1,385 |
| Morphine Sulfate ErMorphine Sulfate | 32 | $938 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Providence
- Kenneth MayerProvidence$129K
- Angela CaliendoProvidence$66K
- Karen TashimaProvidence$8K
- Rami KantorProvidence$3K
- Richa TandonProvidence$2K
- Samira Reyes DassumProvidence$2K
- Michelle LallyProvidence$1K
- Maria MilenoProvidence$516
- Melissa GaitanisProvidence$398
- Sophia PanaccioneProvidence$392
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.